How to Place a Medical Device on the Korean Market in 2026: Import Business Permission versus Item Notification, Certification or Approval, KGMP and QMS Conformity Recognition after Act No. 21263, Official Fees under Enforcement Rule Article 65, and Why CE / 510(k) / NMPA / HSA Do Not Replace an MFDS Licence

Target Audience & Operational Scope: This regulatory guide is designed for international medical device manufacturers, Korea-based importers and distributors, OEM/ODM private-label buyers, and hospital procurement teams evaluating or placing sterile single-use surgical, vascular, and perioperative devices on the Republic of Korea market in 2026. It establishes the exact legal boundaries between Medical Devices Act Articles 6 and 15 business permission, item notification (신고), certification (인증) and approval (허가), KGMP / Act No. 21263 QMS conformity recognition, NIDS delegated administration, live eMedi and Government24 clocks and fees, and the public eMedi directory as a verification limit—not a shipment authorisation.

Table of Contents:

• 1. Does a CE mark, 510(k), NMPA certificate, HSA listing or MDSAP certificate replace Korean item authorisation or import-business permission?
• 2. Who may file: overseas manufacturer, Korean importer, or a consultancy 'Korea License Holder', and which Act articles actually name the roles?
• 3. When is Class I notification enough, when is Class II certification enough, and when does even a Class I or II device need MFDS approval?
• 4. What ISO 13485 proves, what KGMP still requires, and what Act No. 21263 changes from 1 July 2026
• 5. Is the live delegated body NIDS or MDITAC, and why leftover English pages still print MDITAC?
• 6. What the official eMedi and Government24 clocks print versus consultancy 1 / 3–5 / 6–12 month slogans
• 7. What Enforcement Rule Article 65 and Attached Table 10 print for item permission, technical-document review and business permission after 1 July 2026
• 8. What a public eMedi row can and cannot prove, including Samsung Medison versus Weihai Medison
• 9. Which 2026 instruments actually changed the file: 고시 제2026-6호, Notice 2026-34, and Act 21263, versus the stale 2022 English ZIPs
• 10. Worked examples: a CE-marked circumcision ring versus an NMPA-only laser fiber, and a Class I aftercare SKU that must not inherit a copied NMPA class
• 11. Distributor checklist, agreement terms, and red flags before the first Korean shipment
• 12. Where VEMERIX fits—and where due diligence still begins
• 13. Frequently asked questions

Does a CE mark, 510(k), NMPA certificate, HSA listing or MDSAP certificate replace Korean item authorisation or import-business permission?

In international medical device trade, one of the most persistent and costly commercial assumptions is that possessing a prestigious overseas regulatory credential—such as a European CE mark under MDR, a US FDA 510(k) clearance, a China NMPA registration certificate, a Singapore Health Sciences Authority (HSA) listing, or a Medical Device Single Audit Program (MDSAP) certificate—authorizes shipment into the Republic of Korea. It does not. The Ministry of Food and Drug Safety (MFDS) operates an entirely independent, sovereign statutory regime under the Republic of Korea Medical Devices Act (의료기기법) ¹.

Unlike jurisdictions that offer formal expedited reference-agency reliance pathways—such as Singapore's abridged and immediate evaluation routes evaluated in our Singapore HSA market placement guide, or Australia's comparable overseas regulator model detailed in our TGA ARTG inclusion guide—Korea's regulatory framework does not permit foreign clearance to serve as a legal substitute for domestic market authorization. A valid CE certificate or 510(k) summary can serve as supporting technical documentation during technical-document review (기술문서심사), but it does not exempt the product from Korean classification, Korean safety and performance standards, mandatory domestic Good Manufacturing Practice (KGMP) conformity assessment, or the requirement for a licensed Korean importer ².

Similarly, holding an authentic ISO 13485:2016 certificate verified through IAF CertSearch—as outlined in our ISO 13485 certificate verification guide—or an NMPA registration verified per our NMPA registration verification guide provides proof of quality management and country-of-origin authorization, but Korea's statutory regime reserves market entry exclusively to domestic licensed entities. A CE mark or 510(k) can be supporting technical-file evidence; it is not MFDS item authorisation—see how to verify a CE certificate and how to verify a 510(k) clearance. Placing sterile surgical consumables, urological implants, or vascular laser devices on the Korean market requires navigating two distinct statutory tiers: establishing domestic commercial standing and securing product-level authorization.

Who may file: overseas manufacturer, Korean importer, or a consultancy 'Korea License Holder', and which Act articles actually name the roles?

A fundamental barrier encountered by foreign medical device manufacturers seeking market entry into South Korea is the statutory allocation of legal roles. Under the Medical Devices Act, the right to submit a medical device notification, certification, or approval application is restricted to entities established and licensed within the Republic of Korea ²:

• Domestic Manufacturers (제조업자): Regulated under Medical Devices Act Article 6 (제6조 제조업허가 등). Any person intending to manufacture and sell medical devices in Korea must obtain Manufacturing Business Permission from the Regional Food and Drug Administration (지방식품의약품안전청), maintaining compliant manufacturing facilities, quality management systems, and a designated Quality Manager (품질책임자) under Article 6-2.
• Importers (수입업자): Regulated under Medical Devices Act Article 15 (제15조 수입업허가 등). Any person intending to import and sell foreign-manufactured medical devices in Korea must obtain Import Business Permission from the Regional FDA. The importer must maintain appropriate storage facilities, quality control procedures, and appoint a qualified domestic Quality Manager.
• Overseas Manufacturers (해외제조원): Defined as the legal manufacturer located outside Korea. The foreign manufacturing facility cannot apply for, hold, or directly control a Korean medical device license. It acts as the technical documentation supplier and the audited manufacturing site for KGMP assessments.

In commercial marketing and English-language consultancy pitches, the term 'Korea License Holder' (KLH) is ubiquitous. Commercial regulatory consultancies frequently market 'independent KLH representation' services, promising to hold licenses so that manufacturers avoid being captive to a single commercial distributor. However, buyers and regulatory affairs directors must understand that 'Korea License Holder' is not a statutory legal term in Korean law ⁵.

Under the Medical Devices Act, there is no generic 'in-country authorized representative' analogous to an EU Authorised Representative (EC REP) under MDR Article 11 or a UK Responsible Person (UKRP) under Great Britain regulations (examined in our UK MHRA placement guide). The entity holding the Korean item approval or certification is legally the Importer of Record (수입업자) under Article 15. That entity must maintain physical warehousing, retain product liability, manage mandatory domestic adverse event vigilance, employ a certified Quality Manager, and be able to execute the Electronic Standard Customs Clearance Notice (표준통관예정보고) required for medical-device import clearance ¹, ².

Consequently, if an overseas manufacturer contracts a third-party consulting entity to serve as its 'license holder', that consultancy must be an officially permitted medical device import enterprise (수입업체) holding Article 15 business permission. If the manufacturer later switches commercial distributors, transferring the item license requires the formal consent and administrative transfer procedure (양도·양수) of the incumbent importer, underscoring the critical need for well-drafted commercial distribution and IP ownership agreements.

When is Class I notification enough, when is Class II certification enough, and when does even a Class I or II device need MFDS approval?

The Republic of Korea categorizes medical devices into four risk classes (Class I to Class IV) pursuant to Article 3 of the Medical Devices Act and the Enforcement Rule. However, the procedural pathway required to market an item does not depend solely on its numeric risk class. Crucially, the presence of substantial equivalence, novel technological features, or new intended clinical uses dictates whether an item requires administrative notification, delegated certification, or full ministerial approval ¹, ².

1. Class I — Item Notification (품목신고): Applies to low-risk devices under the current Korean item-code rules. Filing is submitted electronically to the National Institute of Medical Device Safety Information (NIDS) under delegated statutory authority. Administrative document review verifies standard product-code mapping and basic labeling compliance. Notification is not a sterile-device exemption: sterile Class I items exist, and KGMP / QMS conformity may still apply depending on the item and manufacturing site.
2. Class II — Item Certification (품목인증): Applies to medium-risk devices that are substantially equivalent (동등제품) to existing, legally marketed Korean devices in intended use, operating principles, raw materials, performance specifications, and sterilization methods. Certification is reviewed and issued by designated third-party Technical Document Review Agencies (민간 기술문서심사기관) under the supervision of NIDS.
3. Class II — Item Approval (품목허가): When a Class II device features modified raw materials, novel energy delivery mechanisms, or expanded clinical indications that preclude a finding of substantial equivalence, it cannot utilize the delegated certification route. It is escalated to formal Item Approval (허가) administered directly by MFDS headquarters or Regional FDAs, requiring rigorous technical document review.
4. Class III & Class IV — Item Approval (품목허가): High-risk devices (e.g., implantable consumables, vascular catheters, active laser delivery systems, specialized tissue adhesives) always require full Item Approval from MFDS headquarters. Applications necessitate exhaustive technical documentation, biocompatibility testing, electrical/mechanical safety reports, and, where applicable, comprehensive clinical trial data (임상시험 성적서).

The operational delineation between these instruments, statutory authorities, and legal rights is summarized in the matrix below:

What ISO 13485 proves, what KGMP still requires, and what Act No. 21263 changes from 1 July 2026

A primary source of distributor friction during Korea market entry is the relationship between international quality management certificates and Korean Good Manufacturing Practice (KGMP). International device manufacturers routinely submit ISO 13485:2016 certificates issued by European notified bodies or registrar bodies, assuming quality clearance is complete. However, ISO 13485 does not equal KGMP ⁸.

KGMP is a statutory conformity assessment governed by the MFDS Standards for Medical Device Manufacturing and Quality Control (의료기기 제조 및 품질관리 기준) ⁸. While the technical requirements of KGMP are closely aligned with ISO 13485:2016, the assessment requires an independent review process. For imported medical devices, the Korean importer and the foreign manufacturing site must jointly apply for KGMP Conformity Assessment (적합성평가) through MFDS or a designated quality audit agency. Depending on device risk classification and whether a physical site audit has occurred previously, the assessment takes the form of an on-site audit (현장조사) or a comprehensive desktop document audit (서류검토) covering site master files, validation reports, sterilization cycle validation (e.g., EO sterilization per ISO 11135), risk management files, and complete batch production records.

Crucially, the regulatory landscape for Korean QMS underwent a fundamental statutory overhaul with the passage of Act No. 21263 (법률 제21263호, Medical Devices Act Partial Amendment), enacted on 30 December 2025 and entering into full legal force on 1 July 2026 ⁵. Prior to Act No. 21263, many operational rules governing QMS audits operated primarily through lower-level MFDS administrative notifications (고시). Act No. 21263 directly elevated and codified QMS conformity into the primary statute:

• Statutory Mandate for QMS Conformity Recognition (Article 28): Article 28 (제28조 제조 및 품질관리체계 적합성인정 등) formally mandates that all medical device manufacturers and importers must undergo QMS evaluation and secure a formal Certificate of Conformity Recognition (적합인정서) from MFDS prior to product distribution, establishing explicit statutory authority for initial, renewal, and change audits.
• Auditor Qualification and Governance (Article 28-2): Article 28-2 (제28조의2 심사원의 임명 및 교육·훈련 등) codifies rigid statutory standards for the appointment, qualification, continuous professional development, and oversight of QMS inspectors, curtailing audit inconsistencies.
• Four-Year Designation and Renewal for Audit Agencies (Articles 6-4 & 28-3): Articles 6-4 and 28-3 introduce a mandatory 4-year validity ceiling on designated third-party Technical Document Review Agencies and QMS Conformity Audit Agencies (적합성인정 업무 대행기관). To continue auditing, agencies must undergo rigorous statutory renewal evaluations before their 4-year term expires, preventing administrative stagnation.
• Sanctions and Revocation for Fraudulent Conformity (Article 28-4): Article 28-4 (제28조의4 적합성인정의 취소 등) establishes clear statutory revocation powers: any conformity recognition secured through false, forged, or fraudulent documentation must be revoked immediately, accompanied by corrective administrative orders under Article 36.
• Statutory Fee Basis for QMS Assessments (Article 50): Article 50 (제50조 수수료) was amended to explicitly incorporate statutory fee collection mechanisms for QMS conformity recognition audits, transitioning QMS fee administration into formal law.
• Affiliated-Institution Sales Restriction (Article 18(5)): Article 18(5) restricts sellers and lessors from supplying devices to medical institutions with which they have a special relationship (특수관계인). It is a Korean sales-order rule, not a blanket ban on importer-to-hospital sales and not a substitute for item licensing.

Regarding the Medical Device Single Audit Program (MDSAP), while Korea MFDS is an official affiliate member of the MDSAP Consortium, an MDSAP certificate does not provide an automatic or complete exemption from KGMP. Commercial consultancies often claim that MDSAP guarantees a 100% desktop audit. In administrative practice, submitting a valid MDSAP audit report covering the foreign site significantly facilitates the desktop review pathway for Class II and certain Class III devices, but the Korean importer must still submit the full domestic KGMP application, pay the statutory assessment fees, and secure the formal Korean Certificate of Conformity Recognition ⁵.

Is the live delegated body NIDS or MDITAC, and why leftover English pages still print MDITAC?

A widespread error encountered in English-language regulatory intelligence—and prominently repeated by major commercial search engines and AI Overviews in September 2026—is the instruction that Class I medical device notifications in South Korea are submitted to 'MDITAC' (Medical Device Information & Technology Assistance Center) ¹.

This guidance is legally obsolete by more than eight years. On 14 June 2018, pursuant to an amendment to Article 42 of the Medical Devices Act, MDITAC was formally restructured, expanded, and renamed as the National Institute of Medical Device Safety Information (NIDS, 한국의료기기안전정보원) ¹, ². NIDS operates as the official statutory public institution under MFDS responsible for:

• Receiving and processing electronic Class I Item Notifications (품목신고);
• Administering and issuing Class II Item Certifications (품목인증) for substantially equivalent medical devices;
• Overseeing designated private-sector Technical Document Review Agencies;
• Managing the national Medical Device Unique Device Identification (UDI) Integrated Information System; and
• Conducting post-market medical device safety monitoring, adverse event surveillance, and supply tracking for orphan and critical-care devices.

Why does the defunct acronym 'MDITAC' continue to contaminate search results and international distributor filings? The root cause is administrative documentation inertia: the official MFDS English portal's 'Approval Process' overview page ¹ continues to display a legacy process diagram created under Law No. 6909 that bears the English label 'MDITAC' on the Class I workflow box. Web-scraping AI engines and overseas consultancies ingest this English graphic without cross-referencing in-force Korean statutory instruments or the live Korean eMedi portal footer, which clearly identifies NIDS (한국의료기기안전정보원) as the statutory operator. Sourcing teams must ensure their regulatory correspondence and vendor questionnaires reflect NIDS, not MDITAC.

What the official eMedi and Government24 clocks print versus consultancy 1 / 3–5 / 6–12 month slogans

When commercial sponsors and distributors plan Korean market entry, they frequently encounter conflicting guidance regarding review timelines. Commercial regulatory consultancies typically publish broad estimates: '1 month for Class I, 3–5 months for Class II, and 6–12 months for Class III/IV'. Those slogans often reflect total calendar duration inclusive of translation, KGMP, and deficiency cycles. They are not the printed service standards on eMedi or Government24 ², ¹⁵, ¹⁶, ¹⁷, ¹⁸.

Live official clocks, copied from eMedi permission guidance and the matching Government24 civil-application cards, are as follows. eMedi prints permission clocks as 'N일 이내' and does not label them '근무일'. Government24 calculates processing periods of six days or more in days excluding Saturdays and public holidays, and periods of five days or less in hours excluding Saturdays and public holidays. 'Working days' is therefore acceptable only when tied to that Government24 counting rule—not as if eMedi printed the English phrase 'working days'.

Distributors and regulatory leads must treat these figures as agency service standards for a complete, accepted file, not as total calendar time to first shipment. The clock starts when the application is formally docketed. It stops when MFDS or NIDS issues a deficiency notice (보완요구서). Time spent preparing supplementary data, additional tests, translations, or a KGMP audit does not count toward the printed 10 / 65 / 80-day or 10 / 42 / 60-day standards. This page does not invent a fixed 30-to-60-calendar-day supplementation window; applicants should read the live deficiency notice for the response period actually granted.

What Enforcement Rule Article 65 and Attached Table 10 print for item permission, technical-document review and business permission after 1 July 2026

Regulatory budgeting for South Korea is frequently plagued by conflicting figures published on commercial consultancy blogs. International sponsors often see quoted figures ranging from a few hundred dollars to tens of thousands. The government application fees that this page treats as independently confirmed sit on the live eMedi fee card (Medical Devices Act Article 50 and Enforcement Rule Article 65) and on Attached Table 10 Item 1 for manufacturing/import business permission ³, ⁴, ¹⁵.

Following the 1 July 2026 Attached Table 10 revision, Korean statutory fees differentiate electronic submissions via eMedi (전자민원) from in-person or postal filings (방문·우편민원). Government24 Class I notification and Class II certification pages point to Attached Table 10 rather than printing those KRW cells. This page therefore does not republish consultancy Class I ₩85,000 / ₩96,000 or Class II certification ₩130,000 / ₩145,000 as official amounts. The independently confirmed card is below:

Distributors evaluating commercial proposals should critically examine consultancy quotes that assert government fees of ₩5,000,000 or more for a standard Class II filing. The live eMedi item-permission card is ₩158,000 / ₩719,000 / ₩1,495,000 electronic depending on review type. Class II certification is a different NIDS instrument; Government24's 인증 page points to Attached Table 10 rather than printing a KRW amount, so this page does not substitute a consultancy ₩130,000 cell. Private testing laboratories and designated review agencies bill separately. Read the live Attached Table 10 for 신고 and 인증 rather than copying an unverified consultancy row ³, ⁴, ¹⁷, ¹⁸.

What a public eMedi row can and cannot prove, including Samsung Medison versus Weihai Medison

The official MFDS Integrated Information System (eMedi) operates a public online database (MNU20237) allowing users to search medical device items, license holders, model numbers, and approval codes. While eMedi is an invaluable research instrument, procurement officers and distributors frequently commit serious due diligence errors by misinterpreting public search results ⁹.

An independent census of the official eMedi extract (273,672 cumulative records through 5 June 2026) is a labelled public-search limitation, not a market-share ranking and not a VEMERIX listing count. Active unique item numbers by recorded class are shown below. Class I 58,754 is the class-tagged unique-item count; one item number (제허23-477호) appears under both Class I and Class IV in the extract, so first-seen-grade counting yields Class I 58,753. Those class codes are directory grades, not proof of 신고 versus 인증 versus 허가 ⁹.

When interpreting eMedi data, due diligence teams must enforce four mandatory verification principles:

1. Active Registrations vs. Historical Shells: Of the 273,672 cumulative rows in the database, only 136,487 rows represent active, legal authorizations (coded as ITEM_STATE='정상' and CANCEL_YN='N'), representing 104,626 unique item numbers held across 6,872 unique licensed corporate entities. Over 137,000 records represent cancelled (취소), expired (만료), withdrawn (취하), or transferred (양도) registrations. A distributor presenting a screenshot of an eMedi record that lacks verified '정상' status is presenting a dead license.
2. Non-Transferability Across Importers: Medical device item approvals in Korea are tied to the specific Korean license holder. If Importer A holds Item License '제수허 24-123호' for a specific foreign device, Importer B cannot ship or clear that identical model through customs under Importer A's number. Importer B must either secure a formal administrative transfer (양도·양수) or submit its own independent import business item application.
3. Manufacturer Country Data Lacuna: In the public eMedi database, the manufacturer-country field is unpopulated on 259,834 out of 273,672 total records. Consequently, running keyword or filter queries for 'China' or '중국' yields an incomplete tally (only 327 total historical rows and 33 active rows). Sourcing staff must not use eMedi country filters as a trade census.
4. Critical Corporate Entity Disambiguation — Samsung Medison vs. Weihai Medison: Across the entire eMedi registry, queries for the string 'medison' yield 357 records across 17 entity names. Crucially, 292 of these records belong to Samsung Medison Co., Ltd. (삼성메디슨(주)), the prominent multinational diagnostic ultrasound manufacturer. Samsung Medison is an entirely separate corporate entity with zero corporate, legal, or manufacturing connection to Weihai Medison Medical Equipment Co., Ltd. (the manufacturer behind the VEMERIX brand). The same identity hygiene is already worked in our Health Canada MDL/MDEL market placement guide: a Samsung Medison ultrasound row is not a Weihai Medison surgical-consumable licence. A procurement officer reviewing an ultrasound license held by Samsung Medison has not verified a VEMERIX surgical consumable or laser fiber.

Furthermore, a public search row on eMedi does not provide legal proof of import clearance. Official document verification requires inspecting the physical or digitally verified Certificate of Item Permission (의료기기 품목허가증) held in the importer's regulatory file, backed by MFDS's official issued-document verification service ¹⁰.

Which 2026 instruments actually changed the file: 고시 제2026-6호, Notification 2026-34, and Act 21263, versus the stale 2022 English ZIPs

Navigating Korean medical device compliance in 2026 requires understanding the exact legislative and administrative updates enacted over the past twelve months. Many overseas compliance teams rely on English translations available on international legal portals or download legacy English ZIP packages from the MFDS archive—such as Prime Minister Ordinance No. 1819 (dated 21 July 2022) ¹¹. These historical translations fail to reflect four major regulatory instruments enacted in 2026, including 고시 제2026-6호, 공고 제2026-167호 / 고시 제2026-34호, Act No. 21263, and the 1 July 2026 Attached Table 10 revision ⁶, ⁷, ¹⁴, ⁵, ⁴:

The relaxation of foreign-document notarization requirements described in Administrative Notice No. 2026-167 and enacted by Notice No. 2026-34 is an efficiency gain for international sponsors where that notice applies. Previously, many foreign technical test reports and manufacturer declarations were handled through consular legalization or apostille practice. Under the in-force 2026 procedure, an official declaration of authenticity executed by the legal manufacturer (제조원 확인서) is accepted in place of notarized non-English translations where the enacted notice so provides ⁷, ¹⁴.

Worked examples: a CE-marked circumcision ring versus an NMPA-only laser fiber, and a Class I aftercare SKU that must not inherit a copied NMPA class

To understand how the Korean placement framework operates in commercial reality, consider three worked scenarios drawn from minimally invasive surgical consumables:

Scenario 1: Auto-Circumcision Anastomat Ring (CE Marked, China NMPA Class II)

Consider a disposable circumcision device such as the public VEMERIX Circumcision Device (self-detaching anastomat ring) ¹². The device holds China NMPA Class II registration (Lu Mech Reg 20172020238), is CE certified under European medical device regulations, and utilizes ethylene oxide (EO) sterilization. A Korean urology distributor wishes to launch the product in Seoul. NMPA Class II and any EU class analogue are not Korean class, and this page does not assign a Korean class or MFDS item number to that SKU.

• Common Error: Sponsoring distributor attempts to import the ring under Class I notification by citing its non-invasive superficial placement, or assumes that possessing European CE certification allows direct customs entry.
• Directory analogue, not a VEMERIX Korean class: In the 5 June 2026 eMedi extract, circumcision-string matches resolve to 10 unique item numbers and 5 active records: four reusable Class I clamps, plus one active Class II 포피제거기 (제허14-1816호) held by (주)지엠디. That is proof a related family appears in the public directory. It is not proof VEMERIX is listed, not a ranking, and not a Korean class assigned to the named SKU. Classify the actual device under current Korean item-code rules before choosing 신고, 인증, or 허가 ⁹.
• Required filings: The Korean distributor must hold an active Article 15 Import Business Permission. The overseas manufacturing facility must undergo KGMP conformity assessment, submitting complete ISO 11135 EO sterilization validation data, ISO 10993 biocompatibility reports, and manufacturing batch records to obtain a Certificate of Conformity Recognition under Act No. 21263. Once KGMP is secured, the importer submits the matching item instrument—notification, certification, or approval—after Korean classification, not after copying NMPA Class II or CE class. The CE technical file provides supporting data, but domestic authorisation must be issued before the first commercial batch ships.

Scenario 2: Disposable Medical Laser Fiber (China NMPA Class II, No CE Claim)

Consider a sterile single-use endovenous laser fiber (radial or bare-tip 1470 nm vascular laser consumable) such as the public VEMERIX Disposable Medical Laser Fiber ¹³. The fiber holds China NMPA Class II registration (Lu Mech Reg 20192010517), pairs with a partner-supplied laser source, and does not hold a separate Medison CE certificate. NMPA Class II is not Korean class, and this page does not assign Class II or Class III to that SKU.

• Common Error: Sponsoring distributor assumes that because the fiber lacks an EU CE mark or US 510(k), it is ineligible for registration in Korea, or conversely conflates the consumable fiber with capital laser consoles (such as the partner-supplied NOVACURE diode laser system).
• Statutory Workflow: Korea MFDS does not require a prior CE mark or 510(k) clearance as a prerequisite for registration. The disposable laser fiber is evaluated strictly on its own merits as a sterile vascular consumable under Korean item classification (의료용레이저조사기용 프로브/파이버).
• Required filings: The Korean importer files for KGMP conformity recognition covering the laser fiber manufacturing site, submitting optical transmission verification, connector mechanics, laser-delivery safety, and sterility-assurance documentation. Classify the fiber under current Korean item-code rules (for example the Korean nomenclature family for medical laser irradiation probes/fibers) and then file the matching 신고, 인증, or 허가 instrument. Possession of NMPA clearance provides manufacturing-consistency evidence; it does not copy a Korean class onto the named SKU, and the partner-supplied NOVACURE console is not a Medison-manufactured capital system.

Scenario 3: Circum-Care Protective Dressing / Underwear (NMPA Class I Trap)

Consider a specialized post-operative protective garment (e.g., Circum-Care Pants) designed with an integrated ventilated dome to shield the surgical site following circumcision. In China, this product may be registered or filed as a Class I medical device or standard sanitary product.

• Common Error: The importer assumes that a Class I classification in China or an FDA general device listing automatically transfers as a Class I Item Notification in Korea.
• Statutory Workflow: Korean classification rules are sovereign. If the product incorporates specialized antibacterial wound contact layers, medical adhesives, or pharmacological substances, Korean classification may escalate the item to a Class II wound dressing (창상피복재) requiring technical review and KGMP certification. Conversely, if it is solely a protective fabric garment without wound contact claims, it may fall outside medical device scope entirely, governed instead as a consumer textile under the Electrical Appliances and Consumer Products Safety Control Act.
• Required Action: Never copy foreign class designations onto Korean applications. The importer must submit an official Classification Inquiry (의료기기 해당여부 및 등급분류 질의) to MFDS prior to filing, establishing whether the SKU is an unclassified consumer good, a Class I notification item, or a Class II medical dressing.

Distributor checklist, agreement terms, and red flags before the first Korean shipment

International medical device manufacturers entering South Korea, as well as hospital procurement teams screening Korean device vendors, must execute a structured, evidence-based due diligence sequence before executing binding distribution contracts or initiating commercial customs export:

1. Verify Importer's Article 15 Business Permission: Demand a certified copy of the Korean partner's Medical Device Import Business Permission Certificate (의료기기 수입업허가증). Confirm that the business address matches physical warehouse facilities and that an active Quality Manager (품질책임자) is formally registered.
2. Determine Sovereign Korean Classification: Do not rely on overseas CE or FDA classification codes. Cross-reference the current MFDS Medical Device Classification and Nomenclature Regulation (의료기기 품목 및 품목별 등급에 관한 규정) for the applicable Korean item classification code (품목분류번호). Do not treat a digit-count slogan as the legal test.
3. Execute Statutory KGMP Audit Pathway: Confirm whether the manufacturing site holds an in-force KGMP Certificate of Conformity Recognition (적합인정서). If filing an initial KGMP application under Act No. 21263, compile the technical documentation dossier: ISO 13485 audit reports, facility layout drawings, cleanroom environmental monitoring reports, sterilization validation (ISO 11135 / ISO 11137), risk management file (ISO 14971), and three consecutive batch manufacturing records.
4. Define License Ownership in Distribution Agreements: Because the item notification, certification, or approval will be held in the Korean importer's corporate name, include strict contractual covenants governing regulatory rights. Stipulate that the importer holds the license as an administrative custodian, mandates immediate regulatory file access for the manufacturer, requires written manufacturer consent prior to filing modifications, and obligates the importer to execute an administrative license transfer (양도·양수) upon commercial contract termination without extortionary transfer fees.
5. Establish Post-Market Vigilance and Complaint Protocol: Establish formal Standard Operating Procedures (SOPs) bridging domestic Korean post-market surveillance duties to the manufacturer's global quality system. Enforce strict notification clocks for adverse events under MFDS regulations, ensuring complaint files are maintained in alignment with global quality requirements (as examined in our QMSR complaint and CAPA file review guide).
6. Korean Labeling and UDI Verification: Review packaging artwork against Medical Devices Act Article 20–22. Verify that labels display the Korean product name, approved license number, manufacturer name and address, importer name and address, lot number, expiration date, sterilization method, and the mandatory Korean Medical Device UDI barcode registered on the NIDS integrated UDI portal.
7. Import clearance notice: Confirm that the importer can execute the Electronic Standard Customs Clearance Notice (표준통관예정보고) required for medical-device import clearance, and that the named importer on that notice matches the Article 15 permission holder and the item-licence holder.

During distributor evaluation, procurement teams must immediately halt transactions if any of the following critical red flags appear:

• Red Flag 1: The distributor claims that goods can ship under a 'Certificate of Free Sale' or CE mark without securing an MFDS item license or import business permission.
• Red Flag 2: The distributor presents an ISO 13485:2016 certificate as proof that 'KGMP is already completed'.
• Red Flag 3: The distributor displays an eMedi public directory search screenshot that displays a status of cancelled (취소), expired (만료), or withdrawn (취하).
• Red Flag 4: The distributor points to an eMedi listing row held by an unrelated corporate entity (such as a Samsung Medison listing) to justify importing a VEMERIX or other manufacturer's SKU.
• Red Flag 5: The regulatory affairs vendor quotes an official government filing fee of ₩5,000,000+ for a standard Class II certification and presents that bundled consultancy total as the MFDS fee card. The live eMedi item-permission card is ₩158,000 / ₩719,000 / ₩1,495,000 electronic depending on review type. Class II 인증 is a different NIDS instrument; read live Attached Table 10 rather than a consultancy ₩130,000 cell.
• Red Flag 6: The distributor insists on submitting filings to 'MDITAC', demonstrating reliance on obsolete, eight-year-old regulatory procedures instead of in-force NIDS protocols.

Where VEMERIX fits—and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery, and perioperative care ¹², ¹³. Across our manufacturing facilities, Weihai Medison maintains certified medical device quality management systems under ISO 13485:2016, holding valid China NMPA Class II medical device registrations across core consumables, alongside CE certification for designated surgical devices including the circumcision anastomat ring ¹².

When partnering with licensed medical device importers and distributor networks in the Republic of Korea, our commercial positioning is anchored strictly in regulatory truth and mutual due diligence:

• Rigorous Dossier Support: We supply comprehensive, audit-ready technical construction files, biocompatibility reports (ISO 10993), sterilization validations (ISO 11135 EO), and factory master files required for Korean desktop KGMP conformity assessment under Act No. 21263.
• Clear Entity Demarcation: We do not assert that VEMERIX directly holds Korean import business permission or domestic MFDS item licenses. In accordance with Medical Devices Act Article 15, Korean authorization must be held by our qualified local importing partners, and we support distributors through every technical query during the NIDS or MFDS review process.
• Accurate Portfolio Truth: We distinguish our self-manufactured consumables from capital equipment. Our vascular line centers on our NMPA-registered single-use medical laser fiber, designed to pair with high-efficiency 1470 nm diode laser sources; we do not manufacture or hold proprietary registration for third-party capital consoles such as the partner-supplied NOVACURE system.
• Corporate Identity Hygiene: We explicitly emphasize to international partners that Weihai Medison Medical Equipment Co., Ltd. is an independent surgical consumables manufacturer and bears no corporate relationship to Samsung Medison Co., Ltd. eMedi ultrasound listings must never be confused with our urological or vascular product lines.

Prospective Korean distributors, OEM private-label partners, and procurement engineers evaluating our circumcision anastomat platform, vascular laser fibers, or perioperative care devices are invited to review our quality systems at VEMERIX Quality & Compliance or initiate a confidential technical file and distributor authorization discussion via VEMERIX Partner Inquiries.

Frequently asked questions

Do I still need MFDS listing if my device already has a CE mark, FDA 510(k) or NMPA certificate?

Yes. A European CE mark, US FDA 510(k) clearance, China NMPA registration, or Singapore HSA listing does not grant legal market access in the Republic of Korea. All medical devices placed on the Korean market must possess a domestic Item Notification (신고), Certification (인증), or Approval (허가) issued under the Medical Devices Act, held by a legally licensed Korean importer or manufacturer ¹, ².

Can the overseas manufacturer file directly, or must a Korean importer hold the licence?

The overseas manufacturer cannot file directly. Under Medical Devices Act Articles 6 and 15, applications must be submitted by an entity incorporated in South Korea that holds official Manufacturing Business Permission (제조업 허가) or Import Business Permission (수입업 허가). For imported medical devices, the Korean importer is the statutory license holder ².

Is a Korea License Holder a legal role in the Medical Devices Act?

No. 'Korea License Holder' (KLH) is commercial consultancy terminology. The Medical Devices Act recognizes only a domestic Manufacturer (제조업자) or Importer (수입업자). A regulatory consultancy acting as a 'license holder' must be an officially permitted import enterprise under Article 15, carrying full legal and post-market product liability under Korean law ⁵.

Does ISO 13485 or MDSAP replace KGMP after 1 July 2026?

No. Standalone ISO 13485:2016 certificates do not replace Korean Good Manufacturing Practice. Effective 1 July 2026, Act No. 21263 codifies mandatory statutory QMS Conformity Recognition (적합성인정) under Article 28. Foreign manufacturing sites must undergo formal desktop or on-site KGMP evaluation by MFDS or designated audit agencies. MDSAP audit reports facilitate the desktop evaluation process but do not eliminate the requirement to obtain an official Korean Certificate of Conformity Recognition ⁵, ⁸.

How much are MFDS item-permission and import-business fees as of 1 July 2026?

Independently confirmed electronic government fees as of 1 July 2026 include: manufacturing/import business permission ₩144,000 (Attached Table 10 Item 1 / Government24); item permission ₩158,000 (other) / ₩719,000 (technical-document review) / ₩1,495,000 (clinical review) on the live eMedi card; plus the eMedi technical-document review, change-permission, reissue, and English-certificate cells listed in Table 3. Class I notification and Class II certification amounts sit on Attached Table 10 and should be read from the live table; Government24's 신고 and 인증 pages point to that table without printing KRW figures. These are government application fees; private testing laboratories and third-party review agencies bill separately ³, ⁴, ¹⁵.

Does another company's eMedi row, or a Samsung Medison listing, cover my shipment of the same model?

No. Korean item approvals are strictly non-transferable across different corporate license holders. Each licensed importer must hold its own product authorization or complete a formal administrative transfer. Furthermore, Samsung Medison Co., Ltd. is an entirely separate corporate entity from Weihai Medison Medical Equipment Co., Ltd.; an eMedi ultrasound record held by Samsung Medison has zero legal relevance to VEMERIX surgical consumables ⁹.

Is MDITAC still the body that accepts Class I notifications?

No. MDITAC was formally restructured and renamed as the National Institute of Medical Device Safety Information (NIDS, 한국의료기기안전정보원) on 14 June 2018 pursuant to Medical Devices Act Article 42. References to MDITAC on English web pages are legacy artifacts; NIDS is the active statutory body processing Class I notifications and Class II certifications ¹, ².

Does VEMERIX already hold an MFDS item licence or Korean import-business permission for these SKUs?

VEMERIX (Weihai Medison Medical Equipment Co., Ltd.) is the foreign legal manufacturer and does not directly hold Korean import business permission or domestic item licenses. Under Korean law, those licenses are held by licensed domestic distribution and importing partners. We provide complete technical construction files, validation dossiers, and KGMP audit support to empower Korean partners to secure and maintain compliant authorizations ¹², ¹³.